- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01554592
Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study
Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin Withdrawal Study.
Heart failure (cardiomyopathy) is a chronic condition in which the heart fails to function as a pump to move blood around the body. This sets up a complex physiologic response to compensate, which include activation of many hormonal mechanisms which result in fluid accumulation.
In recent years, medications to block the hormonal response to heart failure are given as standard drugs, and these include ACE inhibitors and beta blockers. Mortality is reduced with these medications, as well as symptoms improved. Other medications are also used in heart failure, for which a clear-cut benefit has not been demonstrated. Statins, also called HMG CoA reductase inhibitors, are used to reduce cholesterol levels and can help to prevent heart failure by preventing heart attacks. They have been used in heart failure that is not caused by heart attacks in the belief that they had "pleiotropic" effects, meaning that they had beneficial effects in heart failure separate from the reduction in cholesterol.
However large trials in heart failure have demonstrated that statins do not increase survival compared with placebo. There is no evidence to recommend their routine use in established heart failure caused by either heart attacks or genetics.
The investigators propose that the use of statins in heart failure is unnecessary and could be stopped. The importance of finding evidence to cease unproven medications in heart failure cannot be understated. Patients with heart failure take an average of six prescription medications each day. Each medication has side effects and the interactions of all the drugs together are unknown. Statins are the commonest reason for side effects in patients with heart failure, causing muscle pains and gastrointestinal upset.
In this study, the investigators plan to withdraw statins from patients with stable heart failure in a closely monitored environment and watch for the effect of this on heart failure and on how they feel generally.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Clinical Pharmacology, Alfred Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Over the age of 18 years
- Documented heart failure of ischaemic, idiopathic or hypertensive cause
- New York Heart Association (NYHA) class II, III or IV symptoms
- LVEF < 0.40, or no more than 0.35 if NYHA class II and ischaemic aetiology.
- Receiving ACE inhibitor or ARB (Angiotensin II Receptor Blockers), β-blocker and diuretic therapy at the optimal doses.
- Has been receiving statin therapy for at least 3 months
- Willing and able to provide informed consent
Exclusion Criteria:
- Treatment with statins primarily for treatment of hypercholesterolaemia
- Obstructive or restrictive cardiomyopathy
- Uncorrected primary valvular disease
- Active myocarditis
- Decompensated heart failure or a need for inotropic therapy
- Myocardial infarction within the past 6 months
- Unstable angina or stroke within the past 3 months
- PCI (Percutaneous coronary intervention), CABG (coronary artery bypass graft)or implantation of cardioverter-defibrillator or biventricular pacemaker within the past 3 months or a planned implantation of such a device
- Previous or planned cardiac transplantation
- Pericardial disease or systemic disease (eg amyloidosis)
- Acute or chronic liver disease
- Alanine and aspartate transminase concentrations more than 1.5 times the upper limit of normal
- Chronic muscle disease or an unexplained creatinine kinase level of more than 2.5 times the upper limit of normal
- Serum creatinine level greater than 221 micromol/L
- Previous treatment with cyclosporine
- Exercise capacity limited by factors other than cardiac dyspnoea
- Hospitalisation within one month of randomisation
- Pregnant or lactating women or women of childbearing potential who were not adequately protected against becoming pregnant
- Any other concurrent condition that, in the opinion of the investigator, would prevent completion of the clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Statin withdrawal
Participants will received a placebo for 12 weeks.
|
Participants currently received statin therapy will have their statin stopped for 12 weeks.
|
Active Comparator: Stable statin therapy
Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
|
Participants will continue on stable statin therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
NYHA (New York Heart Association) Heart Failure class
Time Frame: baseline and after 12 weeks of treatemnt
|
baseline and after 12 weeks of treatemnt
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
6 minutes walk test
Time Frame: Baseline and after 12 weeks of treatment
|
Baseline and after 12 weeks of treatment
|
Quality of life questionnaire
Time Frame: Baseline and after 12 weeks of treatment
|
Baseline and after 12 weeks of treatment
|
Change in BNP (Brain natriuretic peptide)
Time Frame: Baseline and after 12 weeks of treatment
|
Baseline and after 12 weeks of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Henry Krum, MBBS FRACP PhD, Alfred Hospital/Monash University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-02/12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on Withdrawal of statin therapy
-
University of PadovaCompletedType 2 Diabetes Mellitus | Atherosclerosis | DyslipidemiaItaly
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Idiopathic ArthritisUnited States
-
Royal Brompton & Harefield NHS Foundation TrustUnknown
-
Danish Headache CenterFertility Department, Rigshospitalet, DenmarkCompletedMigraine | Medication Overuse Headache | Endocrine Disorder | DeficiencyDenmark
-
Merck Sharp & Dohme LLCTerminated
-
Endocrine Research SocietyCompleted
-
Medicortex Finland OyTurku University HospitalCompleted
-
Groningen Research Institute for Asthma and COPDCompleted
-
Lithuanian University of Health SciencesKlaipėda University; Minneapolis Heart Institute; Kreiskrankenhaus Rotenburg...Recruiting
-
Samsung Medical CenterNot yet recruitingMetabolic Syndrome | Dyslipidemias | Coronary Artery Calcification